Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.040
-0.050 (-4.59%)
At close: Nov 6, 2026, 4:00 PM EST
1.060
+0.020 (1.92%)
After-hours: Nov 6, 2026, 7:57 PM EST
Allogene Therapeutics Revenue
Allogene Therapeutics had revenue of $4.64M in the twelve months ending September 30, 2026. That makes Allogene Therapeutics the 40,253rd largest company in the world by revenue and 5,344th in the United States.
Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
77.66
Revenue / Employee
$30,526
Employees
152
Market Cap
360.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alector | 173.47M |
| Fennec Pharmaceuticals | 59.22M |
| Prelude Therapeutics | 22.42M |
| Opus Genetics | 9.86M |
| ProKidney | 818.00K |
| Lyell Immunopharma | 15.00K |
ALLO News
- 3 days ago - Allogene Therapeutics reports Q3 EPS (15c), consensus (14c) - TheFly
- 3 days ago - Allogene Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 3 days ago - Allogene Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Allogene Therapeutics Quarterly report: Q3 2026 - Filings
- 3 days ago - Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update - GlobeNewsWire
- 5 days ago - Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting - GlobeNewsWire
- 10 days ago - Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data - GlobeNewsWire
- 13 days ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire